merck

U.S. stocks rallied for the second straight day, ending a tumultuous week on a positive note as investors found more positives than negatives in today's job reports. "It was bad, but not that bad," an investment officer at Wells Fargo told CNBC. "We've made some progress here, we still think we...

After what looked to be another rough day at the open, the markets rebounded and ended down only fractionally. The Dow flat up at 15,440.23. The S&P was down 0.2 percent to 1,751.64 and the NASDAQ was down about 0.5 percent to close at 4,011.55. This morning, U.S. markets are sharply...

U.S. stocks finished the day almost unchanged as investors and traders were presented with a mixed bag of data today. A better than expected report on the service sector negated another report that showed that companies added fewer employees to their payrolls than anticipated in January. The...

Here's a look at the top tickers trending on StockTwits.com Tableau Software: Trouncing estimates Last night, Tableau Software (NASDAQ: DATA) reported its fourth quarter results. The company announced an EPS of $0.20, beating the consensus estimate of $0.00. Revenue of $81.45 million beat the...

January, with its five percent correction, is behind us, and earnings continue to roll out this week, whether or not the groundhog saw his shadow. Highlights will include quarterly results from General Motors (NYSE: GM), Merck (NYSE: MRK), Philip Morris (NYSE: PM) and Walt Disney (NYSE: DIS),...

U.S. stocks fell steeply on Friday as Wall Street recorded its first monthly loss since August. Investors have plenty on their plate to worry about from emerging markets, an earning season failing to ignite excitement and a lackluster consumer confidence that is being felt by many retailers who...

U.S. stocks picked up where they left off on Friday and declined today as investors have plenty on their mind. With earnings being a mixed bag, investors are looking at emerging markets and economic data to support a bullish case for equities. On the emerging market front, investors remain...

Investors and traders were in clear selling mode today ahead of a very busy week of earnings. The Dow suffered a triple digit point loss while the S&P 500 and Nasdaq suffered losses of more than one percent. There were no key economic data releases today. Related: Earnings Expectations For...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages between the November 29 and December 13 settlement dates. Medivation saw its short...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages in late November. Gilead Sciences, Regeneron Pharmaceuticals, Seattle Genetics and...

The earnings crunch rolls on. This week's highlights include quarterly reports from the two biggest companies by market capitalization, Apple and Exxon Mobil, which are expect to post declining earnings. Per-share earnings from General Motors are expected to be the same as a year ago, and...

Among leading biotech and emerging pharmaceutical companies, short sellers retreated from Biogen Idec (NASDAQ: BIIB) by the largest percentage in early October. Amgen (NASDAQ: AMGN), Illumina (NASDAQ: ILMN), Regeneron Pharmaceuticals (NASDAQ: REGN) and Seattle Genetics (NASDAQ: SGEN) saw short...

Among leading biotech and emerging pharmaceutical companies, short sellers moved on Amgen (NASDAQ: AMGN), Pharmacyclics (NASDAQ: PCYC) and Vertex Pharmaceuticals (NASDAQ: VRTX) the most strongly in late September. The number of shares sold short in Dendreon (NASDAQ: DNDN) and Biogen Idec (NASDAQ:...

Declining short interest in Alexion Pharmaceuticals (NASDAQ: ALXN) and Pharmacyclics (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical companies between the August 15 and August 30 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Biogen...

Among leading biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw significant percentage declines in short interest between the July 31 and August 15 settlement dates. Short sellers also shied away...